Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34820
Abstract: BACKGROUND In lung cancer, overexpression of nuclear export proteins can result in inactivation of critical tumor suppressor proteins and cell-cycle regulators. Selective suppression of nuclear export proteins has immunomodulatory activities. Here, clinical safety and early… read more here.
Keywords: lung cancer; safety; combination pembrolizumab; treatment ... See more keywords
Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018;19:405-15.
Sign Up to like & getrecommendations! Published in 2018 at "European urology"
DOI: 10.1016/j.eururo.2018.04.015
Abstract: Atkins and colleagues [1] recently tested the combination of axitinib plus pembrolizumab in previously untreated patients with metastatic clear-cell renal cell carcinoma (RCC). The encouraging results from this phase 1b trial demonstrated that this treatment… read more here.
Keywords: combination pembrolizumab; combination; renal cell; cell ... See more keywords
Abstract A086: Phase Ib study of a novel MDM2 inhibitor APG-115, in combination with pembrolizumab in patients with metastatic solid tumors in U.S.
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-a086
Abstract: Keywords: MDM2; Immuno-oncology; PD-1 Background APG-115 is an orally active small-molecule MDM2 inhibitor that potently binds MDM2 protein, restores TP53 function, and activates p53 - mediated apoptosis in tumor cells retaining wild-type p53. Preclinical studies… read more here.
Keywords: combination pembrolizumab; combination; 115 combination; apg 115 ... See more keywords
Abstract CT093: Axitinib in combination with pembrolizumab (AXI+PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2019-ct093
Abstract: Background: In an open-label, phase Ib dose-finding and dose-expansion study in pts with aRCC, AXI+PEMBRO was tolerable; objective response rate (ORR) was 73.1%, and median progression free survival (mPFS) was 20.9 months (Lancet Oncol. 2018;19:405-15).… read more here.
Keywords: combination pembrolizumab; axitinib combination; pembro; axi pembro ... See more keywords
Abstract CT250: An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct250
Abstract: Background: High-dose interleukin-2 (HD IL-2) induces durable clinical responses in a subset of patients with melanoma and RCC, but severe toxicity limits its therapeutic utility. Early clinical data from several not-α IL-2Rβγ agonists suggest better… read more here.
Keywords: cell; combination pembrolizumab; combination; alone combination ... See more keywords
A phase 1/2 study with birinapant in combination with pembrolizumab.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps3131
Abstract: TPS3131Background: Birinapant is a bivalent SMAC mimetic with activity against multiple members of the inhibitor of apoptosis protein (IAP) family including cIAP1 and has demonstrated tolerability with robust and durable target engagement in advanced cancers.… read more here.
Keywords: combination pembrolizumab; phase; pembrolizumab; phase study ... See more keywords
Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps9117
Abstract: TPS9117Background: Afatinib and pembrolizumab have demonstrated improvements in the outcomes of pts with SCC of the lung and are approved as monotherapy. Afatinib is a selective and irreversible Er... read more here.
Keywords: combination pembrolizumab; pembrolizumab patients; patients pts; afatinib combination ... See more keywords
A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.3125
Abstract: 3125 Background: APG-1387 is a novel, bivalent small molecule IAP (inhibitor of apoptosis proteins) inhibitor. It has shown strong antitumor activities in multiple human xenograft cancer models. APG-1387 also acts as host immune modulator, supporting… read more here.
Keywords: combination pembrolizumab; apg; apg 1387; study ... See more keywords
A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.tps2670
Abstract: TPS2670 Background: The gut microbiome has emerged as a new therapeutic target to augment the efficacy of immune checkpoint blockade. MRx0518 is a novel, gut microbiome-derived, oral live biotherapeutic, designed to induce a broad immunostimulatory… read more here.
Keywords: combination pembrolizumab; mrx0518 combination; oncology; mrx0518 ... See more keywords